ClinicalTrials.gg
CompletedNCT03047408Updated Nov 10, 2026

Evolution of RBD in PD

An interventional study of Video polysomnography in REM Sleep Behavior Disorder and Parkinson's Disease, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Prevention

How we know

Updated Nov 10, 2026Now CompletedResults publication added+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
45 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in REM Sleep Behavior Disorder with a site in France — 6 open to participants now, 6 under way, none of them phase 3. REM Sleep Behavior Disorder · France.

Enrollment
8th of 10
24 · median 54
Started
2017
with 2 others
No phase
10 of 15
3 open now
Registered
3rd of 15
by date
Lead sponsor
6 of 15
University Hospital, Clermont-Ferrand

Among the 15 studies in REM Sleep Behavior Disorder with a site in France, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2017, is one of 10 with no phase, and was the 3rd registered.

REM Sleep Behavior Disorder

101 studies on the registry are indexed under REM Sleep Behavior Disorder; 45 are open to participants now.

Browse REM Sleep Behavior Disorder studies →

Open to participants now

6 of the 15 studies in REM Sleep Behavior Disorder with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 32 REM Sleep Behavior Disorder studies recruiting now, 18 (56%) set no upper age limit and 4 (13%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 45 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in REM Sleep Behavior Disorder with a site in France, or all of them as a file.
02

Study summary

About 60% of Parkinson's Disease (PD) patients have REM sleep Behavior Disorder (RBD), a parasomnia characterized by partial or complete loss of REM sleep muscle atonia and dream-enacting behaviors, usually associated to vivid dreams. The REM Sleep without atonia is the polysomnographic hallmark of RBD, and its quantification is necessary for the diagnosis.

RBD in PD is believed to be a marker of a more widespread degenerative process and a marker of malignant phenotype. Therefore, PD patients with RBD (PD-RBD) are more severely impaired in both motor and non-motor domains, compared to those without RBD, with an increased risk of dementia. However, little is know about the relationship between the evolution of RBD, clinic and video-polysomnographic, and the progression of PD. Besides, an improvement of RBD symptoms is anecdotally reported in PD patients over time. Longitudinal evaluation of RBD in PD, assessed by questionnaires, led to controversial results, but so far, no longitudinal vPSG study has been performed in PD-RBD population.

Thus, the main objective of this study is to longitudinally evaluate clinical and video-polysomnographic features of RBD, including measure of REM Sleep without atonia, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.

Read the detailed description

Type of study: longitudinal study, interventional, cross-sectional;

Number of centres: 1 (Clermont-Ferrand)

Patients: patients with Parkinson's Disease associated with REM sleep behavior disorder (PD-RBD) having already underwent video-polysomnography recording, clinical and neuropsychological evaluation in clinical setting or in the study "RBHP 2013 DURIF " at least three years ago.

Study performance:

This study will be developed in two phases:

  • Phase 1 (Day 0):
  • Verify inclusion criteria, receive informed and written consent;
  • Demographic and clinical characteristics;
  • Neurological evaluation: RBD (RBD severity scale), motor symptoms (Unified Parkinson's Disease Rating Scale, Hoeh et Yahr scale), orthostatic hypotension (Scale for outcomes in PD autonomic questionnaire), behavioral disorders hyper-dopaminergic and hypo-dopaminergic (Ardouin Scale of Behavior in Parkinson's Disease), impulsivity (Test Kirby and Stop signal reaction time)
  • Dreams contents: all patients will receive 3-weeks dream diary;
  • vPSG recording;
  • Self-assessment questionnaires: Non-motor symptoms Questionnaire, Epworth sleepiness scale, Urgency premeditation perseverance and sensation seeking test, Aggressive questionnaire, and the Hospital Anxiety and Depression Rating Scale
  • Phase 2 (+1day): Neuropsychological assessment of:
  • Cognitive function, namely executive functions, visuo-spatial functions, visuo-perceptive functions (Mini mental state examination, California Verbal Learning Test, verbal fluency test, Modified Wisconsin Card Sorting Test, test de Stroop, Digit span, Visual Object and Space Perception Battery, Luria motor sequences, Rey-Osterrieth complex figure)
  • Limbic functions: emotion recognition (Ekman test), apathy (Lille Apathy Rating Scale);
  • Impulsivity and decision-making (Iowa Gambling test).
03

Conditions studied

  • REM Sleep Behavior Disorder
  • Parkinson's Disease

Keywords

  • REM Sleep Behavior Disorder
  • Parkinson's Disease
  • REM sleep without Atonia
04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with clinically confirmed idiopathic Parkinson's Disease, according to the United Kingdom Parkinson Disease Bran Bank criteria, associated with RBD, diagnosed according to the International Classification of Sleep Disorders third edition, that have been already enrolled in the study "RBHP 2013 DURIF", or that have already underwent vPSG recording,clinical and neuropsychiatric evaluation in clinical setting;
  • Male and female aged between 45 to 85 years old;
  • All patients are volunteers and have given written ;
  • All patients are able to understand and to perform all tests included in this protocol;
  • User-friendly in French language, both oral and written

Exclusion criteria

Exclusion Criteria:

  • Patients with neurological diseases other than PD;
  • Patients with psychiatric comorbidities (hallucinations, psychosis) according to the .
  • Patients with Obstructive Sleep Apnea Syndrome (Apnea/hypopnea index >15/h);
  • Patients in guardianship or tutorship;
  • Patients enrolled exclusively in another study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    patients with PD-RBD

    patients with PD-RBD having already underwent vPSG, clinical and neuropsychological in clinical setting or in the study "RBHP 2013 DURIF " at least three years ago.

    Procedure: Video polysomnography

Interventions

  • ProcedureVideo polysomnography

    the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.

06

What researchers measure

Primary outcomes

  1. presence of REM sleep Behavior Disorder confirmed during the video polysomnography

    Time frame: at day 0

Secondary outcomes

  1. The REM sleep Behavior Disorder severity measured by the REM sleep Behavior Disorder scale

    Time frame: at day 0

  2. The Unified Parkinson disease Rating scale score

    Time frame: at day 0

  3. The behavioral disorders measured by the Ardouin Scale of Behavior in Parkinson's Disease score

    Time frame: at day 0

  4. - The Orthostatic hypotension measured by the Scale for outcomes in PD- autonomic questionnaire

    Time frame: at day 0

  5. The impulsivity measured by the Test of Kirby score

    Time frame: at day 0

  6. The impulsivity measured by the Stop signal reaction time score

    Time frame: at day 0

  7. The Hoehn and Yahr scale score

    Time frame: at day 0

  8. The Non-motor symptoms Questionnaire score

    Time frame: at day 0

  9. The Epworth sleepiness scale score

    Time frame: at day 0

  10. The Urgency premeditation perseverance and sensation seeking test

    Time frame: at day 0

  11. The Aggressive questionnaire score

    Time frame: at day 0

  12. The Hospital Anxiety and Depression Rating Scale

    Time frame: at day 0

  13. The dream content

    Time frame: at day 0

  14. The Mini mental state examination score

    Time frame: at day 1

  15. The California Verbal Learning Test score

    Time frame: at day 1

  16. The fluency verbal test score

    Time frame: at day 1

  17. The Modified Wisconsin Card Sorting Test

    Time frame: at day 1

  18. The Stroop score

    Time frame: at day 1

  19. The Empan test score

    Time frame: at day 1

  20. The Visual Object and Space Perception Battery test score

    Time frame: at day 1

  21. The Luria motor sequences

    Time frame: at day 1

  22. The Rey-Osterrieth complex figure

    Time frame: at day 1

  23. The Lille Apathy Rating Scale score

    Time frame: at day 1

  24. The Iowa Gambling test score

    Time frame: at day 1

07

Study locations

1 site
  • Chu Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

References and documents

Publications

  • Figorilli M, Marques AR, Vidal T, Delaby L, Meloni M, Pereira B, Lambert C, Puligheddu M, Durif F, Fantini ML. Does REM sleep behavior disorder change in the progression of Parkinson's disease? Sleep Med. 2020 Apr;68:190-198. doi: 10.1016/j.sleep.2019.12.013. Epub 2020 Jan 10. PubMed 32044557 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2017 to primary completion in Sep 2018, 18 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Apr 2019 → Sep 2018, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2017
First posted
Feb 9, 2017
StartActual
Feb 21, 2017
Primary completionActual
Sep 19, 2018was Apr 2019
CompletionActual
Jun 19, 2019
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 10, 2026
Primary completion
Apr 2019→Sep 19, 2018 (actual)
Nov 10, 2026
Enrollment
50 (estimated)→24 (actual)
Nov 10, 2026
Publications
Results publication added: Figorilli M, Marques AR, Vidal T, Delaby L, Meloni M, Pereira B, Lambert C, Puligheddu M, Durif F, Fantini ML. Does REM sleep behavior disorder change in the p… PubMed 32044557 ↗
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Status unknown→Completed
    Publications Results publication added: Figorilli M, Marques AR, Vidal T, Delaby L, Meloni M, Pereira B, Lambert C, Puligheddu M, Durif F, Fantini ML. Does REM sleep behavior disorder change in the p… PubMed 32044557 ↗
    Primary completion Apr 2019→Sep 19, 2018 (now actual)
    Enrollment 50 (estimated)→24 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03047408
Responsible party
Sponsor
First posted
Feb 9, 2017
Start date
Feb 21, 2017
Primary completion
Sep 19, 2018
Completion
Jun 19, 2019
Last update
Nov 10, 2026

Study contacts

Livia FANTINI
principal investigator · University Hospital, Clermont-Ferrand

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion